LTB and myeloid sarcoma: Another study using anti-VLA4 therapy to identify targeted cell populations was conducted by Kaufmann et al. While tracking CNS-colonizing T cells, a population of pathogenic CD161+ (lymphotoxin beta) LTB+ CD4+ T cells (T09) residing in the brain tissue of progressive MS patients was identified [44].